TenSixteen Bio launched with $40M from Foresite Capital and GV (formerly Google Ventures) on a mission to redefine precision medicine in complex disease by leveraging new insights in somatic mosaicism including clonal hematopoiesis (CHIP).

Incubated by Foresite Labs, the company aims to leverage its platform to address how somatic mutations that accumulate in our blood and other tissues offer new therapeutic avenues for a broad range of diseases including cancer and cardiovascular disease.